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Becker (BMD) and Duchenne muscular dystrophy (DMD) are allelic disorders arising from mutations 
in the dystrophin gene. In-frame mutations lead to the milder BMD while out-of-frame mutations 
disrupt the reading frame and lead to the severe DMD with lack of dystrophin. A therapeutic 
strategy for skipping specific exons in dystrophin and restoring the open reading frame has been 
successfully applied in DMD; this “converts” the out-of-frame deletion in DMD to BMD-like in-frame 
deletion. Micro RNAs (miRs) are small RNA sequences that regulate gene expression post-
transcriptionally. Specific miRs are important regulators of skeletal muscle maintenance. In order to 
better understand the role of miRNAs associated with different levels of dystrophin, we performed 
small RNA sequencing in the muscle samples of BMD patients harbouring deletions relevant to 
ongoing exon skipping studies in DMD. A total of 12 miRs with significant difference between BMD 
and controls were identified including miRs regulating inflammation (miR-146b, miR-155, miR21) 
and vascular angiogenesis (miR-378). BMD patients with dystrophin 70–80% of control levels had 
high expression of miR-425, involved in the regulation of the myostatin signalling pathway. There 
was a significant up-regulation of miR-144 and miR-451 in BMD with lower amounts of dystrophin 
(60–70% of control). These miRNAs are also up-regulated in aged skeletal muscles. The age-
associated changes include loss of muscle mass and altered cycles of degeneration and regeneration 
leading to inflammation that also occurs in DMD and BMD. This suggests a role of miR-144 and miR-
451 in the dystrophic processes. The validation of the identified miRs is ongoing and will help to 
establish the role of the dysregulated miRs in the pathological process in dystrophic muscles. In 
addition to being used as biomarkers, miR425, miR-144 and miR-451 could potentially be utilised as 
therapeutic targets. 
